1361 related articles for article (PubMed ID: 17705444)
1. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
2. Semisynthetic maytansine analogues for the targeted treatment of cancer.
Widdison WC; Wilhelm SD; Cavanagh EE; Whiteman KR; Leece BA; Kovtun Y; Goldmacher VS; Xie H; Steeves RM; Lutz RJ; Zhao R; Wang L; Blättler WA; Chari RV
J Med Chem; 2006 Jul; 49(14):4392-408. PubMed ID: 16821799
[TBL] [Abstract][Full Text] [Related]
3. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
Kellogg BA; Garrett L; Kovtun Y; Lai KC; Leece B; Miller M; Payne G; Steeves R; Whiteman KR; Widdison W; Xie H; Singh R; Chari RV; Lambert JM; Lutz RJ
Bioconjug Chem; 2011 Apr; 22(4):717-27. PubMed ID: 21425776
[TBL] [Abstract][Full Text] [Related]
4. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
5. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA
Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769
[TBL] [Abstract][Full Text] [Related]
6. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
Sun X; Widdison W; Mayo M; Wilhelm S; Leece B; Chari R; Singh R; Erickson H
Bioconjug Chem; 2011 Apr; 22(4):728-35. PubMed ID: 21391620
[TBL] [Abstract][Full Text] [Related]
7. Antibody conjugate therapeutics: challenges and potential.
Teicher BA; Chari RV
Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
[TBL] [Abstract][Full Text] [Related]
8. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.
Jeffrey SC; Andreyka JB; Bernhardt SX; Kissler KM; Kline T; Lenox JS; Moser RF; Nguyen MT; Okeley NM; Stone IJ; Zhang X; Senter PD
Bioconjug Chem; 2006; 17(3):831-40. PubMed ID: 16704224
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.
Zhao RY; Wilhelm SD; Audette C; Jones G; Leece BA; Lazar AC; Goldmacher VS; Singh R; Kovtun Y; Widdison WC; Lambert JM; Chari RV
J Med Chem; 2011 May; 54(10):3606-23. PubMed ID: 21517041
[TBL] [Abstract][Full Text] [Related]
10. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
[TBL] [Abstract][Full Text] [Related]
11. Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
Ricart AD; Tolcher AW
Nat Clin Pract Oncol; 2007 Apr; 4(4):245-55. PubMed ID: 17392715
[TBL] [Abstract][Full Text] [Related]
12. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
[TBL] [Abstract][Full Text] [Related]
13. Antibody drug conjugates - Trojan horses in the war on cancer.
Iyer U; Kadambi VJ
J Pharmacol Toxicol Methods; 2011; 64(3):207-12. PubMed ID: 21843648
[TBL] [Abstract][Full Text] [Related]
14. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
15. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential.
Denora N; Laquintana V; Trapani A; Lopedota A; Latrofa A; Gallo JM; Trapani G
Mol Pharm; 2010 Dec; 7(6):2255-69. PubMed ID: 20958082
[TBL] [Abstract][Full Text] [Related]
16. The next generation of antibody-drug conjugates comes of age.
Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
[TBL] [Abstract][Full Text] [Related]
17. Improving anticancer activity and selectivity of camptothecin through conjugation with releasable substance P.
Zhang W; Song J; Mu L; Zhang B; Liu L; Xing Y; Wang K; Li Z; Wang R
Bioorg Med Chem Lett; 2011 Mar; 21(5):1452-5. PubMed ID: 21282053
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and cytotoxic activities of beta-carboline amino acid ester conjugates.
Zhao M; Bi L; Wang W; Wang C; Baudy-Floc'h M; Ju J; Peng S
Bioorg Med Chem; 2006 Oct; 14(20):6998-7010. PubMed ID: 16806943
[TBL] [Abstract][Full Text] [Related]
19. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
McDonagh CF; Turcott E; Westendorf L; Webster JB; Alley SC; Kim K; Andreyka J; Stone I; Hamblett KJ; Francisco JA; Carter P
Protein Eng Des Sel; 2006 Jul; 19(7):299-307. PubMed ID: 16644914
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.
Dosio F; Brusa P; Cattel L
Toxins (Basel); 2011 Jul; 3(7):848-83. PubMed ID: 22069744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
